INTRODUCTION
Hepatitis B virus (HBV) is a serious global health problem with 2 billion people infected, from which 350 million suffer from chronic hepatitis B worldwide. [1] For the long time, hepatitis B surface antigen (HBs-Ag) positivity has been the classic carrier state; however, it is demonstrated that HBV replication may persist for years in the livers of HBs-Ag negative patients after they have recovered from acute HBV infection. [2, 3] Occult HBV infection (OBI) is defined as the presence of HBV-deoxyribonucleic acid (DNA) in individuals who test negative for HBs-Ag and is more frequent in patients positive for the antibody to hepatitis B core antigen (anti-HBc). [4] The state of suppression of viral replication and gene expression typical of the occult HBV status, leads to a severe and sometimes even fulminant hepatitis B [5] which is an event is usually observed in immunosuppressed patients like human immunodeficiency virus (HIV)-infected ones. In fact, these patients may show a reaction of the viral replication because of the fault of the immunological control which leads to cytotoxic T lymphocytes-medical hepatocyte injury and development of hepatitis. [6] Exposure to HBV infection is common among HIV-infected patients project was approved by the Ethical Committee of Isfahan University of Medical Sciences (research project number: 389301).
The subjects had laboratory confirmed HIV by Western blot and completed a checklist that collected demographic data at enrollment. From each patient, a serum sample was obtained and was stored at −70°C. Clinical and therapeutic data were retrieved from the database of Isfahan Consultation Center for Behavioral Diseases.
Immunologic evaluation for HBs-Ag was performed using enzyme immunoassay test kit (Diapro-Milano-Italy), in accordance with manufacture's specification. Those samples that were negative for HBs-Ag were tested for total anti-HBc by enzyme immunoassay (Diapro-Milano-Italy), and for those that were positive for anti-HBc, HBV-DNA test was done. DNA was extracted from 200 µl of serum using high pure viral Nucleic Acid kit (Roche, Germany). For detection of HBV genomes, samples were assessed by Taqman real-time polymerase chain reaction in the Rotor-Gene Q (QIAGEN. Germany). Analytical studies yielded a limit of detection of 10 IU/ml.
RESULTS
Of 64 HIV-infected patients evaluated in the study, we identified 58 HBs-Ag negative and of them, 12 (20.7%) were anti-HBc positive. HIV acquisition was unknown.
After testing for HBV-DNA, 3 (25%) subjects identified with occult HBV. The plasma HBV-DNA load in the three patients was 357, 536, and 267857 IU/ml. All of them were male and co-infected with hepatitis C virus (HCV). Subjects with and without occult HBV infections were similar with regard to age, use of antiretroviral therapy, CD4 count, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, co-infection with HCV, and routes of HIV transmission. Table 1 presents the clinical and demographic characteristics of these patients.
DISCUSSION
In this study, isolated anti-HBc was detected in 18.75% of the HIV-infected subjects from whom 25% had occult HBV infection. The frequency of isolated anti-HBc in HIVinfected patients is not similar in different studies. [10, 11] About 50% of cases with OHBV infection have been reported to be positive for anti-HBc. [12] The prevalence of occult HBV in HIV-infected patients in previous studies varies from 0% to 89.5% in the world which may be due to the diverse prevalence of hepatitis B and HIV infections in different geographical regions and the sensitivity of the technique used to detect the HBV-DNA. [6, 7] There are some reports in Iran as well. In a study which was carried out in Tehran, Iran, 20.75% of HIV-infected patients had isolated anti-HBc, and HBV-DNA was detected in 13.6% of them. [13] In another study in Tehran, Iran, HBV-DNA was detected in 12 out of 40 (30%) high-risk patients, including HIV-infected and hemodialysis patients with anti-HBc alone. [14] It is demonstrated that, the mortality rate is 19 times higher in co-infected patients than in HIV mono-infected individuals and an increased risk of liver-related morbidity and mortality among HIV-HBV co-infected patients have been indicated. [15] Prior studies among HIV-infected patients found that occult HBV increased the frequency of transaminitis and hepatic flares. [16] We evaluated ALT and AST levels, which are biochemical markers of liver injury. We did not find any correlation between HBV-DNA detection in the plasma and these parameters which may be due to small sample size.
In our study, all of the OHBV patients were HCV infected, which is important. Occult hepatitis B, particularly in HCV-infected subjects may play a role in accelerating the progression of liver disease. [17] Furthermore, patients with chronic hepatitis C and OHBV infection have more frequently lack of response to interferon treatment, and a higher risk of developing hepatocellular carcinoma than those with chronic HCV alone. [18] On the other hand, in patients co-infected with hepatitis and HIV, more sever and end-stage liver disease is declared. [19] Approximately 20% of HIV-infected patients in the world have chronic hepatitis C infection and HCV has emerged as an important cause of morbidity and mortality in these patients. [15] 
